|
|
|
MAKING A CHOICE IN TYPE 2 DIABETES:
CARDIOVASCULAR RISK OR BETA CELL
FUNCTION
Cori Hall
Tuesday, 29 September 2009, 14:30 - 17:00 |
 |
| Co-Chairmen: |
John Betteridge
Professor of Endocrinology and Metabolism,
University College London, UK
Ralph DeFronzo
Professor of Medicine,
University of Texas Health Science Center, San Antonio, US
|
| 14:30 - 14:35 |
Opening remarks
John Betteridge
Professor of Endocrinology and Metabolism, University College
London, UK
|
| 14:35 - 15:00 |
Overcoming the cardio-diabetes epidemic
Mark Kearney
Professor of Cardiology,
University of Leeds, Leeds, UK
|
| 15:00 - 15:25 |
Cardiovascular outcomes in type 2 diabetes:
Measuring successful interventions
Jochen Seufert
Professor of Internal Medicine, Endocrinology and Diabetology,
University of Freiburg, DE
|
| 15:25 - 15:50 |
PROACTIVE: Addressing cardiovascular risk in type 2 diabetes
John Betteridge
Professor of Endocrinology and Metabolism,
University College London, UK
|
| 15:50 - 16:15 |
Future of type 2 diabetes treatment:
Preserving beta cell function
Ralph DeFronzo
Professor of Medicine,
University of Texas Health Science Center, San Antonio, US
|
| 16:15 - 16:40 |
Targeting glycaemic control: What is optimal management?
Guntram Schernthaner
Professor of Medicine and Head of the Department of Medicine,
Rudolfstiftung Hospital, Vienna, AT
|
| 16:40 - 16:55 |
Panel session
|
| 16:55 - 17:00 |
Closing remarks |
For further information please contact:
Website: www.takeda.com / www.lilly.com
Sponsor:
|
|
 |
|
Symposia Programme
